Rwanda Medical Journal
Rwanda Health Communication Center - Rwanda Biomedical Center (RHCC - RBC)
Vol. 78, No. 4, 2021, pp. 5-11
Bioline Code: rw21022
Full paper language: English
Document type: Case Report
Document available free of charge
Rwanda Medical Journal, Vol. 78, No. 4, 2021, pp. 5-11
© Copyright 2021 - The Author(s)
Surfactant therapy for meconium aspiration syndrome in Dr. Soetomo General Hospital – A case series|
Mustakim, M. R. D.; Utomo, M. T.; Etika, R.; Angelika, D.; Handayani, K. D. & Aden, T. Y.
INTRODUCTION: Meconium staining of amniotic fluid (MSAF) is a natural phenomenon in pregnant mothers and their fetuses. MSAF may lead to developing Meconium Aspiration Syndrome (MAS). Surfactant replacement therapy has recently emerged as a therapy in MAS, but no guideline outlines how to administer it properly.
CASE PRESENTATION: We present two-term neonates with severe MAS cases focusing on the bolus surfactant replacement therapy. The first baby was given surfactant at 23 hours after birth and the second baby at 8 hours after birth. We used Survanta (beractant) in the dose of 100 mg/kg BW in both cases. Clinical improvement was observed 24 hours after surfactant bolus administration with different clinical characteristics, treatment approaches, and outcomes.
CONCLUSION: In conclusion, therapeutic surfactant bolus in severe MAS may improve outcomes without significant adverse side effects.
Meconium Aspiration Syndrome; Surfactant; Persistent Fetal Circulation Syndrome; Case Report
Alternative site location: http://www.rwandamedicaljournal.org